NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will release earnings for its first quarter before the opening bell on Monday, May 18.
Analysts expect the Wilmington, Delaware-based company to report quarterly loss of 11 cents per share, versus a loss of 34 cents per share in the year-ago period. The consensus estimate for NRx Pharmaceuticals’ quarterly revenue is $19.43 million, according to Benzinga Pro.
On May 7, NRx Pharma received clearance from the FDA to initiate clinical trial of NRX-101 vs. placebo in patients with depression and suicidality.
NRx Pharmaceuticals shares gained 8.8% to close at $3.21 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- D. Boral Capital analyst Jason Kolbert maintained a Buy rating with a price target of $34 on May 5, 2026. This analyst has an accuracy rate of 47%.
- HC Wainwright & Co. analyst Patrick R. Trucchio maintained a Buy rating with a price target of $45 on April 27, 2026. This analyst has an accuracy rate of 69%.
- Ascendiant Capital analyst Edward Woo maintained a Buy rating and increased the price target from $48 to $49 on April 27, 2026. This analyst has an accuracy rate of 46%.
- BTIG analyst Thomas Shrader maintained a Buy rating with a price target of $25 on March 24, 2026. This analyst has an accuracy rate of 58%.
Considering buying NRXP stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments